InvestorsHub Logo

kevindenver

11/20/19 10:39 AM

#285387 RE: oystersnbeer #285386

Agreed TRTC is very sick, but shareholder value is dead.

All sickness, isn't death.




Simple math shows the equity price will remain under selling pressure from toxic convertible discounted equity debt.

I've been saying for years now "toxic convertible discounted equity notes" will be the downfall of TRTC and a 97% loss since the reverse split was close enough.